Clinical trials: Post Discharge
Healthy
Relative Bioavailability of Telmisartan and Dipyridamole After Co-administration Compared to the Bioavailability of Telmisartan or Dipyridamole Alone in Healthy Female and Male Subjects
To investigate the relative bioavailability of telmisartan respectively of dipyridamole after concomitant administration of 80 mg telmisartan in Micardis® and 25 mg acetylsalicylic acid (ASA)/200 mg extended release (ER)…
- Trial name
- NCT02262793
- Testing
- telmisartan, ASA/ER-DP
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Opioid Analgesia
Pharmacokinetics and Safety of ORF Tablets in Pediatric Patients
The purpose of this study is to characterize the pharmacokinetics (PK) of single-dose ORF tablets in pediatric patients aged 6 to 16 years, inclusive.
- Trial name
- NCT01160614
- Testing
- Oxycodone hydrochloride controlled-release (ORF) tablets
- Where
- 17 sites in United States, Australia and 2 more
- Volunteers
- 30 people
- Sponsor
- Purdue Pharma LP
Attention-deficit Hyperactivity Disorder
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder
This is a phase 1b, multicenter, open-label, multiple-dose trial in pediatric subjects (4 - 12 years of age, inclusive) with a confirmed diagnosis of ADHD.
- Trial name
- NCT04786730
- Testing
- Centanafadine
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Healthy
Clinical Trial to Compare The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg and Immediate Release Formulation
The purpose of this study is to compare the pharmacokinetics profiles of pregabalin sustained release tablet (300mg) to immediate release capsule(150mg * 2) while multiple dosing.
- Trial name
- NCT02103647
- Testing
- Immediate release capsule(lyrica 150mg * 2/day), sustained release tablet
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- IlDong Pharmaceutical Co Ltd
de Novo Kidney Transplantation
Study to Evaluate the Safety and Efficacy of Advagraf vs Prograf in Kidney Transplantation Patients 1 Month After the Transplantation
To investigate the efficacy, safety, and drug compliance of Advagraf® (Extended Release Tacrolimus) by comparing the Advagraf® + steroid + Mycophenolate Mofetil combined therapy and the Prograf® + steroid + Mycophenolate Mofetil…
- Trial name
- AdProCISE (NCT01742624)
- Testing
- Advagraf, Prograf, Corticosteroid
- Where
- 3 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Korea, Inc.
COPD
In This Study, the Sponsor Would Like to Collaborate with Institution and Investigator to Aggregate Participants Data and to Pilot Its Software Algorithm Using Machine Learning and Threshold Based Methods for Predicting Exacerbations and Deterioration Within a 60 Days Period Post-discharge
In this study, the sponsor would like to collaborate with Institution and Investigator to aggregate participants data and to pilot its software algorithm using machine learning and threshold based methods for predicting…
- Trial name
- NCT06798688
- Testing
- A non-invasive cardio-respiratory sensor will be applied on the subjects to measure parameters to identify exacerbations
- Volunteers
- 20 people
- Sponsor
- Respiree Pte Ltd
Postoperative Pain
Safety and Efficacy of Tapentadol Immediate Release (IR) and Oxycodone IR for Treatment of Acute Post-op Pain Following Elective Arthroscopic (Surgery Using a Thin Flexible Scope) Shoulder Surgery
The purpose of this study is to evaluate how tapentadol immediate release (IR) and oxycodone IR treat moderate to severe post-operative pain after elective arthroscopic shoulder surgery.
- Trial name
- NCT00814580
- Testing
- Tapentadol IR, Oxycodone IR
- Volunteers
- 382 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Myelofibrosis, Polycythemia Vera
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in order to select the RP2D for Part 2 of the study.
- Conditions
- Myelofibrosis, Polycythemia Vera, Thrombocythemia
- Trial name
- NCT04629508
- Testing
- itacitinib
- Where
- 21 sites in United States, Austria and 5 more
- Volunteers
- 4 people
- Sponsor
- Incyte Corporation